Provided by the American College of Allergy, Asthma & Immunology
Supported by an independent educational grant from Teva Pharmaceutical Industries Ltd.
Produced by Haymarket Medical Education
Patients with inadequately controlled, severe persistent asthma are at risk for exacerbations, hospitalization, and death and often have impaired quality of life. In a US survey of asthma patients, more than half reported that their disease is uncontrolled. Some patients with severe asthma have persistent daily symptoms and exacerbations despite high doses of inhaled steroids and additional treatment. The increasing prevalence of asthma highlights the need for improved diagnosis and more aggressive and effective treatment. This enduring activity is a video capture of the live Q&A session.
Allergists/immunologists, pulmonologists, primary care and internal medicine physicians, and other healthcare clinicians involved in the treatment of patients with severe asthma
At the conclusion of this activity, participants should be better able to:
Implement stepwise, personalized approaches provided by national and global treatment guidelines and recommendations, such as the NAEPP EPR-3 and GINA, to control symptoms, reduce exacerbations, and improve the quality of life of severe asthma patients
Utilize appropriate treatment strategies for patients with severe persistent asthma whose symptoms are poorly controlled on inhaled corticosteroids
Analyze the safety and efficacy of emerging treatment strategies that are currently being evaluated for poorly controlled asthma
DISCLOSURE POLICY and DISCLOSURES
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program content and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of ACAAI.
All identified conflicts of interest have been resolved.
Bobby Q. Lanier, MD, FACAAI Executive Medical Director American College of Allergy, Asthma & Immunology Clinical Professor of Pediatrics University of North Texas Health Science Center Fort Worth, TX
Program Chair and Moderator Bradley E. Chipps, MD, FACAAI Medical Director, Respiratory Therapy and Cystic Fibrosis Center Sutter Medical Center Capital Allergy & Respiratory Disease Center Sacramento, CA
Rohit K. Katial, MD, FACAAI Professor of Medicine Associate Vice President of Clinical Research & Industry Relationships Co-Director, Asthma Institute Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics Department of Medicine National Jewish Health Denver, CO
Stephen P. Peters, MD, PhD Thomas H. Davis Chair in Pulmonary Medicine Chief, Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases Wake Forest School of Medicine Executive Director, Respiratory Service Line, Wake Forest Baptist Health Wake Forest Baptist Medical Center Winston-Salem, NC
Consultant/Advisor: Array Biopharma, Aerocrine, Airsonett AB, AstraZeneca, Boehringer Ingelheim, Catalyst Biosciences, Experts in Asthma, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, Ono, Pfizer, PPD, Quintiles, Sunovion, Teva, and Theron; Speaker: Merck; Supported/Contracted Research: American Lung Association, National Institutes of Health (NHLBI & NIAID), Actavis, Actelion, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen Biotech, Genentech, GlaxoSmithKline, MedImmune, Novartis, and Sanofi
Education and Publishing Staff/Committee/Reviewers have no relevant financial relationships to disclose, except as may be listed above.
AMA PRA Category 1 Credit(s)TM
The American College of Allergy, Asthma & Immunology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
Unlabeled/investigative uses of therapeutic agents for the treatment of severe asthma are discussed, including lebrikizumab.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American College of Allergy, Asthma & Immunology (ACAAI) or HME. Please refer to the official prescribing information of therapeutic agents regarding approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all preassessment and post-test questions, completed the evaluation, and have received a digital copy of your certificate of credit (physicians) or attendance (other healthcare professionals). Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.